Douglas Goodin, MD

Title(s)Professor, Neurology
SchoolSchool of Medicine
Address675 Nelson Rising Lane, #221D
San Francisco CA 94158
Phone415-750-2011
vCardDownload vCard
    Other Positions
    Title(s)UCSF Weill Institute for Neurosciences


    Collapse Biography 
    Collapse Education and Training
    University of California, San FranciscoResidency School of Medicine - Neurology

    Collapse Overview 

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Multiple sclerosis: Exploring the limits and implications of genetic and environmental susceptibility. PLoS One. 2023; 18(6):e0285599. Goodin DS, Khankhanian P, Gourraud PA, Vince N. PMID: 37379505; PMCID: PMC10306391.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    2. Remote Observational Research for Multiple Sclerosis: A Natural Experiment. Neurol Neuroimmunol Neuroinflamm. 2023 03; 10(2). Bove R, Poole S, Cuneo R, Gupta S, Sabatino J, Harms M, Cooper T, Rowles W, Miller N, Gomez R, Lincoln R, McPolin K, Powers K, Santaniello A, Renschen A, Bevan CJ, Gelfand JM, Goodin DS, Guo CY, Romeo AR, Hauser SL, Campbell Cree BA, UCSF MS-EPIC Team. PMID: 36585249; PMCID: PMC9808915.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansPHPublic Health
    3. Reply to "Spinal Cord Atrophy Is a Preclinical Marker of Progressive MS". Ann Neurol. 2022 05; 91(5):735-736. Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono J, Bevan CJ, Bove RM, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves JS, Green AJ, Oksenberg JR, Waubant E, Wilson MR, Zamvil SS, University of California, San Francisco MS-EPIC Team, Cree BA, Hauser SL, Henry RG. PMID: 35233827; PMCID: PMC9511767.
      View in: PubMed   Mentions:    Fields:    
    4. Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis. Ann Neurol. 2022 02; 91(2):268-281. Bischof A, Papinutto N, Keshavan A, Rajesh A, Kirkish G, Zhang X, Mallott JM, Asteggiano C, Sacco S, Gundel TJ, Zhao C, Stern WA, Caverzasi E, Zhou Y, Gomez R, Ragan NR, Santaniello A, Zhu AH, Juwono J, Bevan CJ, Bove RM, Crabtree E, Gelfand JM, Goodin DS, Graves JS, Green AJ, Oksenberg JR, Waubant E, Wilson MR, Zamvil SS, University of California, San Francisco MS-EPIC Team, Cree BAC, Hauser SL, Henry RG. PMID: 34878197; PMCID: PMC8916838.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    5. Genetic susceptibility to multiple sclerosis in African Americans. PLoS One. 2021; 16(8):e0254945. Goodin DS, Oksenberg JR, Douillard V, Gourraud PA, Vince N. PMID: 34370753; PMCID: PMC8352072.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    6. Genetic susceptibility to multiple sclerosis: interactions between conserved extended haplotypes of the MHC and other susceptibility regions. BMC Med Genomics. 2021 07 10; 14(1):183. Goodin DS, Khankhanian P, Gourraud PA, Vince N. PMID: 34246256; PMCID: PMC8272333.
      View in: PubMed   Mentions: 3     Fields:    
    7. The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS One. 2021; 16(3):e0246157. Goodin DS, Khankhanian P, Gourraud PA, Vince N. PMID: 33750973; PMCID: PMC7984655.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    8. An electronic, unsupervised patient-reported Expanded Disability Status Scale for multiple sclerosis. Mult Scler. 2021 08; 27(9):1432-1441. Romeo AR, Rowles WM, Schleimer ES, Barba P, Hsu WY, Gomez R, Santaniello A, Zhao C, Pearce JR, Jones JB, Cree BC, Hauser SL, Gelfand JM, Stewart WF, Goodin DS, Bove RM. PMID: 33236967; PMCID: PMC8144241.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    9. Neurite Orientation Dispersion and Density Imaging for Assessing Acute Inflammation and Lesion Evolution in MS. AJNR Am J Neuroradiol. 2020 12; 41(12):2219-2226. Sacco S, Caverzasi E, Papinutto N, Cordano C, Bischof A, Gundel T, Cheng S, Asteggiano C, Kirkish G, Mallott J, Stern WA, Bastianello S, Bove RM, Gelfand JM, Goodin DS, Green AJ, Waubant E, Wilson MR, Zamvil SS, Cree BA, Hauser SL, Henry RG, University of California, San Francisco MS-EPIC Team. PMID: 33154077; PMCID: PMC7963254.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    10. Silent progression in disease activity-free relapsing multiple sclerosis. Ann Neurol. 2019 05; 85(5):653-666. University of California, San Francisco MS-EPIC Team, Cree BAC, Hollenbach JA, Bove R, Kirkish G, Sacco S, Caverzasi E, Bischof A, Gundel T, Zhu AH, Papinutto N, Stern WA, Bevan C, Romeo A, Goodin DS, Gelfand JM, Graves J, Green AJ, Wilson MR, Zamvil SS, Zhao C, Gomez R, Ragan NR, Rush GQ, Barba P, Santaniello A, Baranzini SE, Oksenberg JR, Henry RG, Hauser SL. PMID: 30851128; PMCID: PMC6518998.
      View in: PubMed   Mentions: 130     Fields:    Translation:Humans
    11. Predictive validity of NEDA in the 16- and 21-year follow-up from the pivotal trial of interferon beta-1b. Mult Scler. 2019 05; 25(6):837-847. Goodin DS, Reder AT, Traboulsee AL, Li DK, Langdon D, Cutter G, Cook S, O'Donnell T, Kremenchutzky M, Oger J, Koelbach R, Pohl C, Wicklein EM, IFNB Multiple Sclerosis Study Group and the 16- and 21-Year LTF Investigators. PMID: 29761737.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    12. Reply to Tsivgoulis and colleagues comments. Mult Scler Relat Disord. 2018 04; 21:120-121. Goodin DS, Mitsikostas DD. PMID: 29724376.
      View in: PubMed   Mentions: 1     Fields:    
    13. Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS One. 2018; 13(2):e0190043. Goodin DS, Khankhanian P, Gourraud PA, Vince N. PMID: 29438392; PMCID: PMC5810982.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    14. Harnessing electronic medical records to advance research on multiple sclerosis. Mult Scler. 2019 03; 25(3):408-418. Damotte V, Lizée A, Tremblay M, Agrawal A, Khankhanian P, Santaniello A, Gomez R, Lincoln R, Tang W, Chen T, Lee N, Villoslada P, Hollenbach JA, Bevan CD, Graves J, Bove R, Goodin DS, Green AJ, Baranzini SE, Cree BA, Henry RG, Hauser SL, Gelfand JM, Gourraud PA. PMID: 29310490.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    15. Comparing the efficacy of disease-modifying therapies in multiple sclerosis. Mult Scler Relat Disord. 2017 Nov; 18:109-116. Mitsikostas DD, Goodin DS. PMID: 29141791.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. Long-term evolution of multiple sclerosis disability in the treatment era. Ann Neurol. 2016 10; 80(4):499-510. University of California, San Francisco MS-EPIC Team:, Cree BA, Gourraud PA, Oksenberg JR, Bevan C, Crabtree-Hartman E, Gelfand JM, Goodin DS, Graves J, Green AJ, Mowry E, Okuda DT, Pelletier D, von Büdingen HC, Zamvil SS, Agrawal A, Caillier S, Ciocca C, Gomez R, Kanner R, Lincoln R, Lizee A, Qualley P, Santaniello A, Suleiman L, Bucci M, Panara V, Papinutto N, Stern WA, Zhu AH, Cutter GR, Baranzini S, Henry RG, Hauser SL. PMID: 27464262; PMCID: PMC5105678.
      View in: PubMed   Mentions: 140     Fields:    Translation:Humans
    17. Incidence and course of depression in multiple sclerosis in the multinational BEYOND trial. J Neurol. 2016 Jul; 263(7):1418-26. Schippling S, O'Connor P, Knappertz V, Pohl C, Bogumil T, Suarez G, Cook S, Filippi M, Hartung HP, Comi G, Jeffery DR, Kappos L, Goodin DS, Arnason B. PMID: 27177997; PMCID: PMC4929160.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    18. The nature of genetic susceptibility to multiple sclerosis: constraining the possibilities. BMC Neurol. 2016 Apr 27; 16:56. Goodin DS. PMID: 27117889; PMCID: PMC4847201.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    19. The epidemiology of multiple sclerosis: insights to a causal cascade. Handb Clin Neurol. 2016; 138:173-206. Goodin DS. PMID: 27637959.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    20. Association of Vitamin D Levels With Multiple Sclerosis Activity and Progression in Patients Receiving Interferon Beta-1b. JAMA Neurol. 2015 Dec; 72(12):1458-65. Fitzgerald KC, Munger KL, Köchert K, Arnason BG, Comi G, Cook S, Goodin DS, Filippi M, Hartung HP, Jeffery DR, O'Connor P, Suarez G, Sandbrink R, Kappos L, Pohl C, Ascherio A. PMID: 26458124.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    21. A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. Mult Scler. 2016 09; 22(10):1349-58. Collins CD, Ivry B, Bowen JD, Cheng EM, Dobson R, Goodin DS, Lechner-Scott J, Kappos L, Galea I. PMID: 26564998; PMCID: PMC5015760.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    22. Relapses in multiple sclerosis: Relationship to disability. Mult Scler Relat Disord. 2016 Mar; 6:10-20. Goodin DS, Reder AT, Bermel RA, Cutter GR, Fox RJ, John GR, Lublin FD, Lucchinetti CF, Miller AE, Pelletier D, Racke MK, Trapp BD, Vartanian T, Waubant E. PMID: 27063617.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    23. Predictors of disease activity in 857 patients with MS treated with interferon beta-1b. J Neurol. 2015 Nov; 262(11):2466-71. Hartung HP, Kappos L, Goodin DS, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Petkau J, White R, Bogumil T, Beckmann K, Stemper B, Suarez G, Sandbrink R, Pohl C. PMID: 26239222; PMCID: PMC4639578.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    24. Association Between Thoracic Spinal Cord Gray Matter Atrophy and Disability in Multiple Sclerosis. JAMA Neurol. 2015 Aug; 72(8):897-904. Schlaeger R, Papinutto N, Zhu AH, Lobach IV, Bevan CJ, Bucci M, Castellano A, Gelfand JM, Graves JS, Green AJ, Jordan KM, Keshavan A, Panara V, Stern WA, von Büdingen HC, Waubant E, Goodin DS, Cree BA, Hauser SL, Henry RG. PMID: 26053119; PMCID: PMC6002864.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    25. Haplotype-based approach to known MS-associated regions increases the amount of explained risk. J Med Genet. 2015 Sep; 52(9):587-94. Khankhanian P, Gourraud PA, Lizee A, Goodin DS. PMID: 26185143; PMCID: PMC4552900.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    26. Patient preferences for attributes of multiple sclerosis disease-modifying therapies: development and results of a ratings-based conjoint analysis. Int J MS Care. 2015 Mar-Apr; 17(2):74-82. Wilson LS, Loucks A, Gipson G, Zhong L, Bui C, Miller E, Owen M, Pelletier D, Goodin D, Waubant E, McCulloch CE. PMID: 25892977; PMCID: PMC4399770.
      View in: PubMed   Mentions: 36  
    27. Precision medicine in chronic disease management: The multiple sclerosis BioScreen. Ann Neurol. 2014 Nov; 76(5):633-42. Gourraud PA, Henry RG, Cree BA, Crane JC, Lizee A, Olson MP, Santaniello AV, Datta E, Zhu AH, Bevan CJ, Gelfand JM, Graves JS, Goodin DS, Green AJ, von Büdingen HC, Waubant E, Zamvil SS, Crabtree-Hartman E, Nelson S, Baranzini SE, Hauser SL. PMID: 25263997; PMCID: PMC4214886.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    28. Causes of death among commercially insured multiple sclerosis patients in the United States. PLoS One. 2014; 9(8):e105207. Goodin DS, Corwin M, Kaufman D, Golub H, Reshef S, Rametta MJ, Knappertz V, Cutter G, Pleimes D. PMID: 25144226; PMCID: PMC4140735.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    29. Spinal cord gray matter atrophy correlates with multiple sclerosis disability. Ann Neurol. 2014 Oct; 76(4):568-80. Schlaeger R, Papinutto N, Panara V, Bevan C, Lobach IV, Bucci M, Caverzasi E, Gelfand JM, Green AJ, Jordan KM, Stern WA, von Büdingen HC, Waubant E, Zhu AH, Goodin DS, Cree BA, Hauser SL, Henry RG. PMID: 25087920; PMCID: PMC5316412.
      View in: PubMed   Mentions: 79     Fields:    Translation:Humans
    30. Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices. J Neurol Sci. 2014 Sep 15; 344(1-2):80-7. Wilson L, Loucks A, Bui C, Gipson G, Zhong L, Schwartzburg A, Crabtree E, Goodin D, Waubant E, McCulloch C. PMID: 25037284.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    31. Single nucleotide polymorphism (SNP)-strings: an alternative method for assessing genetic associations. PLoS One. 2014; 9(4):e90034. Goodin DS, Khankhanian P. PMID: 24727690; PMCID: PMC3984082.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    32. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014 Jun; 13(6):545-56. Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, Vollmer T, Agius MA, Kappos L, Stites T, Li B, Cappiello L, von Rosenstiel P, Lublin FD. PMID: 24685276.
      View in: PubMed   Mentions: 325     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    33. The epidemiology of multiple sclerosis: insights to disease pathogenesis. Handb Clin Neurol. 2014; 122:231-66. Goodin DS. PMID: 24507521.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansAnimals
    34. Preface. Handb Clin Neurol. 2014; 122:ix-x. Goodin DS. PMID: 24507541.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimals
    35. Glucocorticoid treatment of multiple sclerosis. Handb Clin Neurol. 2014; 122:455-64. Goodin DS. PMID: 24507531.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansPHPublic Health
    36. Survival in commercially insured multiple sclerosis patients and comparator subjects in the U.S. Mult Scler Relat Disord. 2014 May; 3(3):364-71. Kaufman DW, Reshef S, Golub HL, Peucker M, Corwin MJ, Goodin DS, Knappertz V, Pleimes D, Cutter G. PMID: 25876474.
      View in: PubMed   Mentions: 12     Fields:    
    37. Interleukin 17F level and interferon β response in patients with multiple sclerosis. JAMA Neurol. 2013 Aug; 70(8):1017-21. Hartung HP, Steinman L, Goodin DS, Comi G, Cook S, Filippi M, O'Connor P, Jeffery DR, Kappos L, Axtell R, Knappertz V, Bogumil T, Schwenke S, Croze E, Sandbrink R, Pohl C. PMID: 23732754; PMCID: PMC4290836.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    38. Mortality in patients with multiple sclerosis. Neurology. 2013 Jul 09; 81(2):184-92. Scalfari A, Knappertz V, Cutter G, Goodin DS, Ashton R, Ebers GC. PMID: 23836941; PMCID: PMC3770174.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    39. The use of interferon Beta and glatiramer acetate in multiple sclerosis. Semin Neurol. 2013 Feb; 33(1):13-25. Goodin DS. PMID: 23709209.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    40. The genetic and environmental bases of complex human-disease: extending the utility of twin-studies. PLoS One. 2012; 7(12):e47875. Goodin DS. PMID: 23272039; PMCID: PMC3525648.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansPHPublic Health
    41. Cause of death in MS: long-term follow-up of a randomised cohort, 21 years after the start of the pivotal IFNβ-1b study. BMJ Open. 2012; 2(6). Goodin DS, Ebers GC, Cutter G, Cook SD, O'Donnell T, Reder AT, Kremenchutzky M, Oger J, Rametta M, Beckmann K, Knappertz V. PMID: 23204140; PMCID: PMC3533062.
      View in: PubMed   Mentions: 18     Fields:    
    42. Response to GS Gronseth and E Ashman. Mult Scler. 2012 Nov; 18(11):1661-2; author reply 1663-4. Goodin DS, Reder AT. PMID: 23100528.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    43. Treatment with interferon beta for multiple sclerosis. JAMA. 2012 Oct 24; 308(16):1627; author reply 1627-8. Goodin DS, Reder AT, Cutter G. PMID: 23093155.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    44. Evidence-based medicine: promise and pitfalls. Mult Scler. 2012 Jul; 18(7):947-8. Goodin DS, Reder AT. PMID: 22740607.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    45. Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies. J Neuroinflammation. 2012 Jun 15; 9:129. Hartung HP, Kieseier B, Goodin DS, Arnason BG, Comi G, Cook S, Filippi M, Jeffery DR, Kappos L, Bogumil T, Stemper B, Sandbrink R, Nakada Y, Nakajima H, Schwenke S, Lehr S, Heubach J, Pohl C, Reischl J. PMID: 22703536; PMCID: PMC3403940.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    46. Acute hypercalcemia following excessive calcium supplementation in a dehydrated patient with progressive multiple sclerosis: vitamin d supplementation is a red herring-reply. Arch Neurol. 2012 Jun 01; 69(6):793-4. Marcus JF, Goodin DS, Harris CA, Josephson SA. PMID: 23753930.
      View in: PubMed   Mentions:    Fields:    
    47. Retinal axonal loss begins early in the course of multiple sclerosis and is similar between progressive phenotypes. PLoS One. 2012; 7(5):e36847. Gelfand JM, Goodin DS, Boscardin WJ, Nolan R, Cuneo A, Green AJ. PMID: 22666330; PMCID: PMC3359324.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCells
    48. Survival in MS: a randomized cohort study 21 years after the start of the pivotal IFNβ-1b trial. Neurology. 2012 Apr 24; 78(17):1315-22. Goodin DS, Reder AT, Ebers GC, Cutter G, Kremenchutzky M, Oger J, Langdon D, Rametta M, Beckmann K, DeSimone TM, Knappertz V. PMID: 22496198; PMCID: PMC3335454.
      View in: PubMed   Mentions: 80     Fields:    Translation:Humans
    49. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the American Clinical Neurophysiology Society. Neurology. 2012 Feb 21; 78(8):585-9. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, American Clinical Neurophysiology Society. PMID: 22351796.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    50. Evidence-based guideline update: intraoperative spinal monitoring with somatosensory and transcranial electrical motor evoked potentials*. J Clin Neurophysiol. 2012 Feb; 29(1):101-8. Nuwer MR, Emerson RG, Galloway G, Legatt AD, Lopez J, Minahan R, Yamada T, Goodin DS, Armon C, Chaudhry V, Gronseth GS, Harden CL, American Association of Neuromuscular and Electrodiagnostic Medicine. PMID: 22353994.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    51. Severe hypercalcemia following vitamin d supplementation in a patient with multiple sclerosis: a note of caution. Arch Neurol. 2012 Jan; 69(1):129-32. Marcus JF, Shalev SM, Harris CA, Goodin DS, Josephson SA. PMID: 22232355.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    52. Relationship between early clinical characteristics and long term disability outcomes: 16 year cohort study (follow-up) of the pivotal interferon β-1b trial in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2012 Mar; 83(3):282-7. Goodin DS, Traboulsee A, Knappertz V, Reder AT, Li D, Langdon D, Wolf C, Beckmann K, Konieczny A, Ebers GC, 16-Year Long Term Follow-up Study Investigators. PMID: 22193561.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    53. Genome-wide meta-analysis identifies novel multiple sclerosis susceptibility loci. Ann Neurol. 2011 Dec; 70(6):897-912. Patsopoulos NA, Bayer Pharma MS Genetics Working Group, Steering Committees of Studies Evaluating IFNß-1b and a CCR1-Antagonist, ANZgene Consortium, GeneMSA, International Multiple Sclerosis Genetics Consortium, Esposito F, Reischl J, Lehr S, Bauer D, Heubach J, Sandbrink R, Pohl C, Edan G, Kappos L, Miller D, Montalbán J, Polman CH, Freedman MS, Hartung HP, Arnason BG, Comi G, Cook S, Filippi M, Goodin DS, Jeffery D, O'Connor P, Ebers GC, Langdon D, Reder AT, Traboulsee A, Zipp F, Schimrigk S, Hillert J, Bahlo M, Booth DR, Broadley S, Brown MA, Browning BL, Browning SR, Butzkueven H, Carroll WM, Chapman C, Foote SJ, Griffiths L, Kermode AG, Kilpatrick TJ, Lechner-Scott J, Marriott M, Mason D, Moscato P, Heard RN, Pender MP, Perreau VM, Perera D, Rubio JP, Scott RJ, Slee M, Stankovich J, Stewart GJ, Taylor BV, Tubridy N, Willoughby E, Wiley J, Matthews P, Boneschi FM, Compston A, Haines J, Hauser SL, McCauley J, Ivinson A, Oksenberg JR, Pericak-Vance M, Sawcer SJ, De Jager PL, Hafler DA, de Bakker PI. PMID: 22190364; PMCID: PMC3247076.
      View in: PubMed   Mentions: 182     Fields:    Translation:Humans
    54. Establishing long-term efficacy in chronic disease: use of recursive partitioning and propensity score adjustment to estimate outcome in MS. PLoS One. 2011; 6(11):e22444. Goodin DS, Jones J, Li D, Traboulsee A, Reder AT, Beckmann K, Konieczny A, Knappertz V, 16-Year Long-Term Follow-up Study Investigators. PMID: 22140424; PMCID: PMC3227563.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    55. Incorporating neutralizing antibody assays into routine clinical practice: a long and arduous road. Mult Scler. 2011 Nov; 17(11):1274-5. Goodin DS. PMID: 22058084.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    56. Neutralizing antibodies to interferon beta-1b multiple sclerosis: a clinico-radiographic paradox in the BEYOND trial. Mult Scler. 2012 Feb; 18(2):181-95. Goodin DS, Hartung HP, O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Jeffery D, Kappos L, Bogumil T, Knappertz V, Sandbrink R, Beckmann K, White R, Petkau J, Pohl C, BEYOND Study Group. PMID: 21952094.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    57. Multiple Sclerosis: The Big Questions- The MS Forum Workshop. Int MS J. 2011 Sep; 17(3):100-7. Goodin D. PMID: 21689494.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    58. Interferon β-1b and glatiramer acetate effects on permanent black hole evolution. Neurology. 2011 Apr 05; 76(14):1222-8. Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. PMID: 21464426; PMCID: PMC3068007.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    59. Switching multiple sclerosis patients with breakthrough disease to second-line therapy. PLoS One. 2011 Feb 03; 6(2):e16664. Castillo-Trivino T, Mowry EM, Gajofatto A, Chabas D, Crabtree-Hartman E, Cree BA, Goodin DS, Green AJ, Okuda DT, Pelletier D, Zamvil SS, Vittinghoff E, Waubant E. PMID: 21304907; PMCID: PMC3033401.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    60. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011 Feb 22; 76(8):686-92. Okuda DT, Mowry EM, Cree BA, Crabtree EC, Goodin DS, Waubant E, Pelletier D. PMID: 21270417; PMCID: PMC3053327.
      View in: PubMed   Mentions: 74     Fields:    Translation:Humans
    61. The genetic basis of multiple sclerosis: a model for MS susceptibility. BMC Neurol. 2010 Oct 28; 10:101. Goodin DS. PMID: 21029420; PMCID: PMC2994805.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    62. Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis. Ann Neurol. 2010 Aug; 68(2):145-50. Cree BA, Kornyeyeva E, Goodin DS. PMID: 20695007.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    63. Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial. J Neurol Neurosurg Psychiatry. 2010 Aug; 81(8):907-12. Ebers GC, Traboulsee A, Li D, Langdon D, Reder AT, Goodin DS, Bogumil T, Beckmann K, Wolf C, Konieczny A, Investigators of the 16-year Long-Term Follow-Up Study. PMID: 20562430.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    64. Cross-sectional study assessing long-term safety of interferon-beta-1b for relapsing-remitting MS. Neurology. 2010 Jun 08; 74(23):1877-85. Reder AT, Ebers GC, Traboulsee A, Li D, Langdon D, Goodin DS, Bogumil T, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study. PMID: 20530324.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    65. Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode. Mult Scler. 2009 Oct; 15(10):1175-82. Goodin DS, Bates D. PMID: 19737851.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    66. 250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study. Lancet Neurol. 2009 Oct; 8(10):889-97. O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T, BEYOND Study Group, O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Harung HP, Kappos L, Jeffery D, Comi G. PMID: 19729344.
      View in: PubMed   Mentions: 129     Fields:    Translation:HumansCTClinical Trials
    67. Long-term follow-up of the original interferon-beta1b trial in multiple sclerosis: design and lessons from a 16-year observational study. Clin Ther. 2009 Aug; 31(8):1724-36. Ebers GC, Reder AT, Traboulsee A, Li D, Langdon D, Goodin DS, Wolf C, Beckmann K, Konieczny A, Investigators of the 16-Year Long-Term Follow-Up Study. PMID: 19808131.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    68. Quality of life in multiple sclerosis is associated with lesion burden and brain volume measures. Neurology. 2009 May 19; 72(20):1760-5. Mowry EM, Beheshtian A, Waubant E, Goodin DS, Cree BA, Qualley P, Lincoln R, George MF, Gomez R, Hauser SL, Okuda DT, Pelletier D. PMID: 19451531; PMCID: PMC2683738.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    69. Results of using a wireless inertial measuring system to quantify gait motions in control subjects. IEEE Trans Inf Technol Biomed. 2010 Jul; 14(4):904-15. Tien I, Glaser SD, Bajcsy R, Goodin DS, Aminoff MJ. PMID: 19423449.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    70. The 2nd world congress on controversies in neurology. Int MS J. 2009 Apr; 16(1):33-4. Goodin D. PMID: 19413925.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    71. Magnetic resonance imaging as a surrogate for treatment effect on multiple sclerosis relapses. Ann Neurol. 2009 Mar; 65(3):237-8. Arnold DL, Goodin DS. PMID: 19334057.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    72. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One. 2009; 4(2):e4565. Goodin DS. PMID: 19242548; PMCID: PMC2644781.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansPHPublic Health
    73. Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome. Neurology. 2009 Mar 03; 72(9):800-5. Okuda DT, Mowry EM, Beheshtian A, Waubant E, Baranzini SE, Goodin DS, Hauser SL, Pelletier D. PMID: 19073949.
      View in: PubMed   Mentions: 156     Fields:    Translation:Humans
    74. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology. 2008 Dec 09; 71(24 Suppl 3):S8-13. Goodin DS. PMID: 19064873.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    75. Genotype-Phenotype correlations in multiple sclerosis: HLA genes influence disease severity inferred by 1HMR spectroscopy and MRI measures. Brain. 2009 Jan; 132(Pt 1):250-9. Okuda DT, Srinivasan R, Oksenberg JR, Goodin DS, Baranzini SE, Beheshtian A, Waubant E, Zamvil SS, Leppert D, Qualley P, Lincoln R, Gomez R, Caillier S, George M, Wang J, Nelson SJ, Cree BA, Hauser SL, Pelletier D. PMID: 19022862; PMCID: PMC2638695.
      View in: PubMed   Mentions: 53     Fields:    Translation:Humans
    76. Electrical brain events associated with awareness of errors. Brain Res. 2009 Jan 28; 1251:213-22. Ralph JW, Goodin DS, Long JM, Aminoff MJ. PMID: 19046953.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    77. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009 Feb 15; 18(4):767-78. Baranzini SE, Wang J, Gibson RA, Galwey N, Naegelin Y, Barkhof F, Radue EW, Lindberg RL, Uitdehaag BM, Johnson MR, Angelakopoulou A, Hall L, Richardson JC, Prinjha RK, Gass A, Geurts JJ, Kragt J, Sombekke M, Vrenken H, Qualley P, Lincoln RR, Gomez R, Caillier SJ, George MF, Mousavi H, Guerrero R, Okuda DT, Cree BA, Green AJ, Waubant E, Goodin DS, Pelletier D, Matthews PM, Hauser SL, Kappos L, Polman CH, Oksenberg JR. PMID: 19010793; PMCID: PMC4334814.
      View in: PubMed   Mentions: 199     Fields:    Translation:Humans
    78. Assessment: the use of natalizumab (Tysabri) for the treatment of multiple sclerosis (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2008 Sep 02; 71(10):766-73. Goodin DS, Cohen BA, O'Connor P, Kappos L, Stevens JC, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. PMID: 18765653.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    79. The impact of war-stress on MS exacerbations. Ann Neurol. 2008 Aug; 64(2):114-5. Goodin DS. PMID: 18626947.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    80. Comparative studies of glatiramer acetate and interferon beta. Int MS J. 2008 Jun; 15(2):39-41. Goodin D. PMID: 18782497.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study. Clin Ther. 2008 Jun; 30(6):1102-12. Hurwitz BJ, Jeffery D, Arnason B, Bigley K, Coyle P, Goodin D, Kaba S, Kirzinger S, Lynch S, Mandler R, Mikol D, Rammohan K, Sater R, Sriram S, Thrower B, Boateng F, Jakobs P, Wash MB, Bogumil T. PMID: 18640466.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    82. Electrophysiological evaluation of dementia. Handb Clin Neurol. 2008; 89:63-74. Aminoff MJ, Goodin DS. PMID: 18631731.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    83. Integrating an evidence-based assessment of benefit and risk in disease-modifying treatment of multiple sclerosis. Curr Med Res Opin. 2007 Nov; 23(11):2823-32. Goodin DS, Biermann LD, Bohlega S, Boiko A, Chofflon M, Gebeily S, Gouider R, Havrdova E, Jakab G, Karabudak R, Karussis D, Miller A, Pakdaman H, Selmaj K, Sharief M, International Working Group for Treatment Optimization in MS. PMID: 17908370.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    84. Neutralizing antibodies to interferon beta: assessment of their clinical and radiographic impact: an evidence report: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2007 Mar 27; 68(13):977-84. Goodin DS, Frohman EM, Hurwitz B, O'Connor PW, Oger JJ, Reder AT, Stevens JC. PMID: 17389300.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    85. Neutralizing antibodies to interferon beta-1b are not associated with disease worsening in multiple sclerosis. J Int Med Res. 2007 Mar-Apr; 35(2):173-87. Goodin DS, Hurwitz B, Noronha A. PMID: 17542405.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    86. Age at disability milestones in multiple sclerosis and history of multiple sclerosis: a unifying concept. Brain. 2006 Dec; 129(Pt 12):e56; author reply e57. Goodin D. PMID: 17132635.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    87. A randomized study of two interferon-beta treatments in relapsing-remitting multiple sclerosis. Neurology. 2006 Oct 10; 67(7):1313-4. Goodin DS. PMID: 17030783.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    88. The use of MRI in the diagnosis of multiple sclerosis. Lancet Neurol. 2006 Oct; 5(10):808-9. Goodin D. PMID: 16987725.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    89. IM interferon beta-1a delays definite multiple sclerosis 5 years after a first demyelinating event. Neurology. 2006 Sep 26; 67(6):1104; author reply 1104-5. Goodin DS. PMID: 17000997.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    90. Interferon beta in relapsing-remitting multiple sclerosis: an eight years experience in a specialist multiple sclerosis centre. J Neurol. 2006 Jul; 253(7):947-8; author reply 949. Goodin DS. PMID: 16845567.
      View in: PubMed   Mentions:    Fields:    Translation:HumansPHPublic Health
    91. The return of natalizumab: weighing benefit against risk. Lancet Neurol. 2006 May; 5(5):375-7. Goodin D. PMID: 16632301.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    92. Magnetic resonance imaging as a surrogate outcome measure of disability in multiple sclerosis: have we been overly harsh in our assessment? Ann Neurol. 2006 Apr; 59(4):597-605. Goodin DS. PMID: 16566022.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    93. Overdiagnosis of multiple sclerosis by magnetic resonance imaging. Ann Neurol. 2006 Mar; 59(3):575-6; author reply 576. Goodin DS, Frohman EM. PMID: 16489616.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    94. Response to interferon beta-1a treatment in African American multiple sclerosis patients. Arch Neurol. 2005 Nov; 62(11):1681-3. Cree BA, Al-Sabbagh A, Bennett R, Goodin D. PMID: 16286540.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    95. Treatment of multiple sclerosis with human beta interferon. Int MS J. 2005 Nov; 12(3):96-108. Goodin DS. PMID: 16417818.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    96. Evidence-based medicine. Int MS J. 2005 Nov; 12(3):94-5. Goodin DS. PMID: 16422017.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    97. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci. 2005 Dec 15; 239(1):67-74. Panitch H, Goodin D, Francis G, Chang P, Coyle P, O'Connor P, Li D, Weinshenker B, EVIDENCE (EVidence of Interferon Dose-response: European North American Comparative Efficacy) Study . PMID: 16169561.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansPHPublic Health
    98. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study. Arch Neurol. 2005 May; 62(5):785-92. Schwid SR, Thorpe J, Sharief M, Sandberg-Wollheim M, Rammohan K, Wendt J, Panitch H, Goodin D, Li D, Chang P, Francis G, EVIDENCE (Evidence of Interferon Dose-Response: European North American Comparative Efficacy) Study , University of British Columbia MS/MRI Research Group. PMID: 15883267.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    99. Clinical characteristics of African Americans vs Caucasian Americans with multiple sclerosis. Neurology. 2004 Dec 14; 63(11):2039-45. Cree BA, Khan O, Bourdette D, Goodin DS, Cohen JA, Marrie RA, Glidden D, Weinstock-Guttman B, Reich D, Patterson N, Haines JL, Pericak-Vance M, DeLoa C, Oksenberg JR, Hauser SL. PMID: 15596747.
      View in: PubMed   Mentions: 100     Fields:    Translation:Humans
    100. Disease-modifying therapy in MS: a critical review of the literature. Part I: Analysis of clinical trial errors. J Neurol. 2004 Sep; 251 Suppl 5:v3-v11. Goodin DS. PMID: 15549352.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    101. Disease-modifying therapy in MS: a critical review of the literature. Part II: Assessing efficacy and dose-response. J Neurol. 2004 Sep; 251 Suppl 5:v50-v56. Goodin DS. PMID: 15549356.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    102. Assessment: transcranial Doppler ultrasonography: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2004 May 11; 62(9):1468-81. Sloan MA, Alexandrov AV, Tegeler CH, Spencer MP, Caplan LR, Feldmann E, Wechsler LR, Newell DW, Gomez CR, Babikian VL, Lefkowitz D, Goldman RS, Armon C, Hsu CY, Goodin DS, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. PMID: 15136667.
      View in: PubMed   Mentions: 132     Fields:    Translation:Humans
    103. Relationship between multiple sclerosis exacerbations and stress. Psychosom Med. 2004 Mar-Apr; 66(2):287-9; author reply 287-9. Goodin DS. PMID: 15039517.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Marijuana and multiple sclerosis. Lancet Neurol. 2004 Feb; 3(2):79-80. Goodin D. PMID: 14746994.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    105. Mapping multiple sclerosis susceptibility to the HLA-DR locus in African Americans. Am J Hum Genet. 2004 Jan; 74(1):160-7. Oksenberg JR, Barcellos LF, Cree BA, Baranzini SE, Bugawan TL, Khan O, Lincoln RR, Swerdlin A, Mignot E, Lin L, Goodin D, Erlich HA, Schmidt S, Thomson G, Reich DE, Pericak-Vance MA, Haines JL, Hauser SL. PMID: 14669136; PMCID: PMC1181903.
      View in: PubMed   Mentions: 129     Fields:    Translation:Humans
    106. Stimulus recognition and its relationship to the cerebral event-related potential. Neurology. 2003 Dec 09; 61(11):1533-7. Leppert D, Goodin DS, Aminoff MJ. PMID: 14663038.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    107. The use of mitoxantrone (Novantrone) for the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Nov 25; 61(10):1332-8. Goodin DS, Arnason BG, Coyle PK, Frohman EM, Paty DW, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. PMID: 14638950.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    108. The utility of MRI in suspected MS: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 2003 Sep 09; 61(5):602-11. Frohman EM, Goodin DS, Calabresi PA, Corboy JR, Coyle PK, Filippi M, Frank JA, Galetta SL, Grossman RI, Hawker K, Kachuck NJ, Levin MC, Phillips JT, Racke MK, Rivera VM, Stuart WH, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. PMID: 12963748.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    109. Interferons in relapsing remitting multiple sclerosis. Lancet. 2003 May 24; 361(9371):1821; author reply 1823-4. Goodin DS. PMID: 12781556.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    110. HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course. Am J Hum Genet. 2003 Mar; 72(3):710-6. Barcellos LF, Oksenberg JR, Begovich AB, Martin ER, Schmidt S, Vittinghoff E, Goodin DS, Pelletier D, Lincoln RR, Bucher P, Swerdlin A, Pericak-Vance MA, Haines JL, Hauser SL, Multiple Sclerosis Genetics Group. PMID: 12557126; PMCID: PMC1180245.
      View in: PubMed   Mentions: 81     Fields:    Translation:Humans
    111. Disease-modifying Therapies for Multiple Sclerosis. Curr Treat Options Neurol. 2003 Jan; 5(1):35-54. Corboy JR, Goodin DS, Frohman EM. PMID: 12521562.
      View in: PubMed   Mentions: 8  
    112. Neuromyelitis optica. Semin Neurol. 2002 Jun; 22(2):105-22. Cree BA, Goodin DS, Hauser SL. PMID: 12524556.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimals
    113. Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines. Neurology. 2002 Jan 22; 58(2):169-78. Goodin DS, Frohman EM, Garmany GP, Halper J, Likosky WH, Lublin FD, Silberberg DH, Stuart WH, van den Noort S, Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS . PMID: 11805241.
      View in: PubMed   Mentions: 193     Fields:    Translation:Humans
    114. Assessment: prevention of post-lumbar puncture headaches: report of the therapeutics and technology assessment subcommittee of the american academy of neurology. Neurology. 2000 Oct 10; 55(7):909-14. Evans RW, Armon C, Frohman EM, Goodin DS. PMID: 11061243.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    115. Clinical utility of surface EMG: report of the therapeutics and technology assessment subcommittee of the American Academy of Neurology. Neurology. 2000 Jul 25; 55(2):171-7. Pullman SL, Goodin DS, Marquinez AI, Tabbal S, Rubin M. PMID: 10908886.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    116. Therapeutic developments in multiple sclerosis. Expert Opin Investig Drugs. 2000 Apr; 9(4):655-70. Goodin DS. PMID: 11060700.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    117. Studies of the human stretch reflex. Muscle Nerve Suppl. 2000; 9:S3-6. Aminoff MJ, Goodin DS. PMID: 11135278.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. The cladribine trial in secondary progressive MS: response. Neuroepidemiology. 2000 Jan-Feb; 19(1):53-4. Goodin DS. PMID: 10654289.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    119. Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch in patients with Huntington's disease. Muscle Nerve. 1999 Nov; 22(11):1557-63. Siedenberg R, Goodin DS, Aminoff MJ. PMID: 10514234.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    120. The relationship of MS to physical trauma and psychological stress: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology. 1999 Jun 10; 52(9):1737-45. Goodin DS, Ebers GC, Johnson KP, Rodriguez M, Sibley WA, Wolinsky JS. PMID: 10371517.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    121. Order effects in response times of parkinsonian patients and normal controls. Muscle Nerve. 1999 May; 22(5):567-72. Goodin DS, Aminoff MJ, Kutukcu Y, Marks WJ. PMID: 10331354.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. Survey of multiple sclerosis in northern California. Northern California MS Study Group. Mult Scler. 1999 Apr; 5(2):78-88. Goodin DS. PMID: 10335515.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    123. Interferon beta treatment for multiple sclerosis. Lancet. 1999 Feb 06; 353(9151):495-6; author reply 497-8. Goodin DS. PMID: 9989741.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    124. Simple and choice reaction time in Parkinson's disease. Brain Res. 1999 Jan 09; 815(2):367-72. Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ. PMID: 9878832.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    125. Perils and pitfalls in the interpretation of clinical trials: a reflection on the recent experience in multiple sclerosis. Neuroepidemiology. 1999; 18(2):53-63. Goodin DS. PMID: 10023128.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    126. Cognitive event-related potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52:91-5. Heinze HJ, Münte TF, Kutas M, Butler SR, Näätänen R, Nuwer MR, Goodin DS. PMID: 10590979.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    127. Somatosensory evoked potentials. The International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol Suppl. 1999; 52:79-90. Mauguière F, Allison T, Babiloni C, Buchner H, Eisen AA, Goodin DS, Jones SJ, Kakigi R, Matsuoka S, Nuwer M, Rossini PM, Shibasaki H. PMID: 10590978.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    128. A questionnaire to assess neurological impairment in multiple sclerosis. Mult Scler. 1998 Oct; 4(5):444-51. Goodin DS. PMID: 9839306.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    129. Cerebral accompaniments to simple and choice reaction tasks in Parkinson's disease. Brain Res. 1998 Jul 13; 799(1):1-5. Kutukcu Y, Marks WJ, Goodin DS, Aminoff MJ. PMID: 9666054.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    130. Cognitive event-related potentials. J Clin Neurophysiol. 1998 Jan; 15(1):2. Goodin DS. PMID: 9502508.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    131. Event-related potentials in the study of sensory discrimination and motor response in simple and choice reaction tasks. J Clin Neurophysiol. 1998 Jan; 15(1):34-43. Goodin DS, Aminoff MJ. PMID: 9502511.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    132. The decision to make a movement: neurophysiological insights. Can J Neurol Sci. 1997 Aug; 24(3):181-90. Aminoff MJ, Goodin DS. PMID: 9276102.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    133. Changes of forearm EMG and cerebral evoked potentials following sudden muscle stretch during isometric contractions in patients with Parkinson's disease. Brain Res. 1997 May 23; 757(2):254-9. Aminoff MJ, Siedenberg R, Goodin DS. PMID: 9200754.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    134. Response compatibility and the relationship between event-related potentials and the timing of a motor response. J Neurophysiol. 1996 Dec; 76(6):3705-13. Goodin DS, Aminoff MJ, Chequer RS, Ortiz TA. PMID: 8985868.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    135. Nonrandom behavior in a reaction-time time series. Muscle Nerve. 1996 Sep; 19(9):1183-5. Goodin DS, Aminoff MJ. PMID: 8761281.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    136. Comparison of late components in simultaneously recorded event-related electrical potentials and event-related magnetic fields. Electroencephalogr Clin Neurophysiol. 1996 Aug; 99(2):191-7. Siedenberg R, Goodin DS, Aminoff MJ, Rowley HA, Roberts TP. PMID: 8761055.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    137. Response times and handedness in simple reaction-time tasks. Exp Brain Res. 1996 Apr; 109(1):117-26. Goodin DS, Aminoff MJ, Ortiz TA, Chequer RS. PMID: 8740214.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    138. Side effect profile of interferon beta-1b in MS: results of an open label trial. Neurology. 1996 Feb; 46(2):552-4. Neilley LK, Goodin DS, Goodkin DE, Hauser SL. PMID: 8614531.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    139. The frontal N30 component of the median-derived SEP in patients with predominantly unilateral Parkinson's disease. Neurology. 1995 May; 45(5):989-92. Garcia PA, Aminoff MJ, Goodin DS. PMID: 7746421.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    140. Visual evoked potentials. J Clin Neurophysiol. 1994 Sep; 11(5):493-9. Aminoff MJ, Goodin DS. PMID: 7844240.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    141. Biochemical alterations in multiple sclerosis lesions and normal-appearing white matter detected by in vivo 31P and 1H spectroscopic imaging. Ann Neurol. 1994 Aug; 36(2):157-65. Husted CA, Goodin DS, Hugg JW, Maudsley AA, Tsuruda JS, de Bie SH, Fein G, Matson GB, Weiner MW. PMID: 8053651.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    142. In vivo detection of myelin phospholipids in multiple sclerosis with phosphorus magnetic resonance spectroscopic imaging. Ann Neurol. 1994 Aug; 36(2):239-41. Husted CA, Matson GB, Adams DA, Goodin DS, Weiner MW. PMID: 8053662.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    143. IFCN recommended standards for brain-stem auditory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):12-7. Nuwer MR, Aminoff M, Goodin D, Matsuoka S, Mauguière F, Starr A, Vibert JF. PMID: 7517839.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    144. IFCN recommended standards for long-latency auditory event-related potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):18-20. Goodin D, Desmedt J, Maurer K, Nuwer MR. PMID: 7517840.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    145. IFCN recommended standards for short latency somatosensory evoked potentials. Report of an IFCN committee. International Federation of Clinical Neurophysiology. Electroencephalogr Clin Neurophysiol. 1994 Jul; 91(1):6-11. Nuwer MR, Aminoff M, Desmedt J, Eisen AA, Goodin D, Matsuoka S, Mauguière F, Shibasaki H, Sutherling W, Vibert JF. PMID: 7517845.
      View in: PubMed   Mentions: 41     Fields:    Translation:Humans
    146. Late electromyographic activity following stretch in human forearm muscles: physiological role. Brain Res. 1994 Apr 04; 641(2):273-8. Chequer RS, Goodin DS, Aminoff MJ, Maeztu C. PMID: 8012828.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCells
    147. Treatment of optic neuritis. Neurology. 1993 Dec; 43(12):2731-2. Goodin DS. PMID: 8255497.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    148. Expectancy and response strategy to sensory stimuli. Neurology. 1993 Oct; 43(10):2139-42. Goodin DS, Aminoff MJ, Ortiz TA. PMID: 8413982.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    149. Neural processing in a three-choice reaction-time task: a study using cerebral evoked-potentials and single-trial analysis in normal humans. J Neurophysiol. 1993 May; 69(5):1499-512. Ortiz TA, Goodin DS, Aminoff MJ. PMID: 8509828.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    150. Corticosteroids and optic neuritis. Neurology. 1993 Mar; 43(3 Pt 1):632-3; author reply 633-4. Goodin DS. PMID: 8451021.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    151. Evaluation of dementia by event-related potentials. J Clin Neurophysiol. 1992 Oct; 9(4):521-5. Goodin DS, Aminoff MJ. PMID: 1464678.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    152. The basis and functional role of the late EMG activity in human forearm muscles following wrist displacement. Brain Res. 1992 Aug 28; 589(1):39-47. Goodin DS, Aminoff MJ. PMID: 1422820.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    153. Effect of different high-pass filters on the long-latency event-related auditory evoked potentials in normal human subjects and individuals infected with the human immunodeficiency virus. J Clin Neurophysiol. 1992 Jan; 9(1):97-104. Goodin DS, Aminoff MJ, Chequer RS. PMID: 1552013.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    154. The nature of suprasegmental influences on the late reflex activity in human forearm muscles. Brain Res. 1991 Dec 06; 566(1-2):284-9. Chequer RS, Goodin DS, Aminoff MJ. PMID: 1814545.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    155. The use of immunosuppressive agents in the treatment of multiple sclerosis: a critical review. Neurology. 1991 Jul; 41(7):980-5. Goodin DS. PMID: 2067661.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    156. A comparison of magnetic and electrical stimulation of peripheral nerves. Muscle Nerve. 1990 Oct; 13(10):957-63. Olney RK, So YT, Goodin DS, Aminoff MJ. PMID: 2233853.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    157. Organization of sensory discrimination and response selection in choice and nonchoice conditions: a study using cerebral evoked potentials in normal humans. J Neurophysiol. 1990 Oct; 64(4):1270-81. Goodin DS, Aminoff MJ, Shefrin SL. PMID: 2258747.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCells
    158. Evidence that the long-latency stretch responses of the human wrist extensor muscle involve a transcerebral pathway. Brain. 1990 Aug; 113 ( Pt 4):1075-91. Goodin DS, Aminoff MJ, Shih PY. PMID: 2397383.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    159. Clinical utility of long latency 'cognitive' event-related potentials (P3): the pros. Electroencephalogr Clin Neurophysiol. 1990 Jul; 76(1):2-5; discussion 1. Goodin DS. PMID: 1694481.
      View in: PubMed   Mentions: 14     Fields:    Translation:Humans
    160. Long latency event-related potentials in patients infected with human immunodeficiency virus. Ann Neurol. 1990 Apr; 27(4):414-9. Goodin DS, Aminoff MJ, Chernoff DN, Hollander H. PMID: 2353795.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    161. Detection of epileptiform activity by different noninvasive EEG methods in complex partial epilepsy. Ann Neurol. 1990 Mar; 27(3):330-4. Goodin DS, Aminoff MJ, Laxer KD. PMID: 2327741.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    162. Electrophysiological features of the dementia of Parkinson's disease. Adv Neurol. 1990; 53:361-3. Aminoff MJ, Goodin A, Goodin DS. PMID: 2146859.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    163. Effects of different sensory inputs on the median-derived somatosensory evoked potential. Muscle Nerve. 1989 Jul; 12(7):598-603. Reisin RC, Goodin DS, Aminoff MJ, Mantle MM. PMID: 2674707.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    164. Effect of reference point on visual evoked potentials: clinical relevance. Electroencephalogr Clin Neurophysiol. 1988 Jul-Aug; 71(4):319-22. Shih PY, Aminoff MJ, Goodin DS, Mantle MM. PMID: 2454798.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    165. Recovery of peripheral and central responses to median nerve stimulation. Electroencephalogr Clin Neurophysiol. 1988 Jun; 69(6):585-8. Reisin RC, Goodin DS, Aminoff MJ, Mantle MM. PMID: 2453337.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    166. Dermatomal somatosensory evoked potentials in lumbosacral root compression. J Neurol Neurosurg Psychiatry. 1988 May; 51(5):740-2. Aminoff MJ, Goodin DS. PMID: 3404181; PMCID: PMC1033097.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    167. Magnetic resonance imaging in amyotrophic lateral sclerosis. Ann Neurol. 1988 Apr; 23(4):418-20. Goodin DS, Rowley HA, Olney RK. PMID: 3382182.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    168. Ambulatory EEG recordings in epileptic and nonepileptic children. Neurology. 1988 Apr; 38(4):558-62. Aminoff MJ, Goodin DS, Berg BO, Compton MN. PMID: 3352910.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    169. PD and ciladopa. Neurology. 1988 Jan; 38(1):167. Goodin DS, Aminoff MJ. PMID: 3336454.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    170. Visual evoked potentials in the investigation of "blindsight". Neurology. 1988 Jan; 38(1):104-9. Shefrin SL, Goodin DS, Aminoff MJ. PMID: 3336441.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    171. Sensory discrimination and its relationship to the cerebral processing of infrequent stimuli. Can J Neurol Sci. 1987 Nov; 14(4):642-8. Goodin DS, Aminoff MJ, Mantle MM. PMID: 3690439.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    172. Treatment of Parkinson's disease with ciladopa. Ann Neurol. 1987 Mar; 21(3):311. Aminoff MJ, Goodin DS, Habermann-Little B, Cutler JR. PMID: 3606037.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    173. Electrophysiological evidence of visual processing in a blind field. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40:752-5. Shefrin SL, Goodin DS, Aminoff MJ. PMID: 3480204.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    174. The distinction between different types of dementia using evoked potentials. Electroencephalogr Clin Neurophysiol Suppl. 1987; 40:695-8. Goodin DS, Aminoff MJ. PMID: 2961553.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    175. Electrophysiological differences between demented and nondemented patients with Parkinson's disease. Ann Neurol. 1987 Jan; 21(1):90-4. Goodin DS, Aminoff MJ. PMID: 3827218.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    176. Electrophysiological differences between subtypes of dementia. Brain. 1986 Dec; 109 ( Pt 6):1103-13. Goodin DS, Aminoff MJ. PMID: 2947660.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    177. Subclasses of event-related potentials: response-locked and stimulus-locked components. Ann Neurol. 1986 Nov; 20(5):603-9. Goodin DS, Aminoff MJ, Mantle MM. PMID: 3789674.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    178. P300 latency as a biologic marker of dementia. Biol Psychiatry. 1986 Oct; 21(12):1111-3. Goodin DS. PMID: 3756261.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    179. Acute syphilitic meningitis. Its occurrence after clinical and serologic cure of secondary syphilis with penicillin G. Arch Neurol. 1986 Feb; 43(2):137-8. Bayne LL, Schmidley JW, Goodin DS. PMID: 3947251.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    180. Electrophysiologic evaluation of lumbosacral radiculopathies: electromyography, late responses, and somatosensory evoked potentials. Neurology. 1985 Oct; 35(10):1514-8. Aminoff MJ, Goodin DS, Parry GJ, Barbaro NM, Weinstein PR, Rosenblum ML. PMID: 2993952.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    181. Electrophysiologic evaluation of dementia. Neurol Clin. 1985 Aug; 3(3):633-47. Goodin DS. PMID: 3900684.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    182. Task-dependent hemisphere asymmetries of the visual evoked potential. Neurology. 1985 Mar; 35(3):378-84. Goodin DS, Waltz DA, Aminoff MJ. PMID: 3974896.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    183. Dermatomal somatosensory evoked potentials in unilateral lumbosacral radiculopathy. Ann Neurol. 1985 Feb; 17(2):171-6. Aminoff MJ, Goodin DS, Barbaro NM, Weinstein PR, Rosenblum ML. PMID: 2983601.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    184. Does the interictal EEG have a role in the diagnosis of epilepsy? Lancet. 1984 Apr 14; 1(8381):837-9. Goodin DS, Aminoff MJ. PMID: 6143148.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    185. The relationship between the evoked potential and brain events in sensory discrimination and motor response. Brain. 1984 Mar; 107 ( Pt 1):241-51. Goodin DS, Aminoff MJ. PMID: 6697158.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    186. Sequential changes in the P3 component of the auditory evoked potential in confusional states and dementing illnesses. Neurology. 1983 Sep; 33(9):1215-8. Goodin DS, Starr A, Chippendale T, Squires KC. PMID: 6684260.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    187. Variations in early and late event-related components of the auditory evoked potential with task difficulty. Electroencephalogr Clin Neurophysiol. 1983 Jun; 55(6):680-6. Goodin DS, Squires KC, Starr A. PMID: 6189698.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    188. Long latency event-related components of the auditory evoked potential in dementia. Brain. 1978 Dec; 101(4):635-48. Goodin DS, Squires KC, Starr A. PMID: 737523.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    189. An early event-related cortical potential. Psychophysiology. 1978 Jul; 15(4):360-5. Goodin DS, Squires KC, Henderson BH, Starr A. PMID: 693744.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    190. Age-related variations in evoked potentials to auditory stimuli in normal human subjects. Electroencephalogr Clin Neurophysiol. 1978 Apr; 44(4):447-58. Goodin DS, Squires KC, Henderson BH, Starr A. PMID: 76553.
      View in: PubMed   Mentions: 64     Fields:    Translation:Humans
    191. Mutant of bacteriophage T4D affecting expression of many early genes. Nature. 1974 Jul 05; 250(461):48-50. Mattson T, Richardson J, Goodin D. PMID: 4601455.
      View in: PubMed   Mentions: 29     Fields:    Translation:Cells
    With one click, see people who:

    Mentor Faculty

    Run Clinical Trials

    Work in Global Health Equity

    Offer Student Projects

    See more options in the Advanced Search tab

    Douglas's Networks
    Concepts (421)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (42)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCSF Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).

    We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use. This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB04.

    Copyright © The Regents of the University of California.